Timothy Kennedy, MD, MBA
Dr. Timothy Kennedy is a surgical oncologist with special expertise in minimally invasive approaches to upper gastrointestinal malignancies and peritoneal malignancies, including peritoneal mesothelioma. He practices and is an Assistant Professor of Surgery at the Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.[1]
Dr. Kennedy’s skills include advanced laparoscopic and robotic techniques for GI cancers, as well as cytoreductive surgery and hyperthermic intraperitoneal (HIPEC) for the treatment of peritoneal surface malignancies and mesothelioma. As a member of the Gastrointestinal/Hepatobiliary Program and Mesothelioma Treatment and Research Program at Rutgers Cancer Institute, he works with medical oncologists, radiation oncologists, gastroenterologists, pulmonologists, and radiologists to create individualized treatment plans that deliver the best possible outcome and quality of life.
Education and Career
Dr. Kennedy attended Georgetown University for his undergraduate education, and after earning his bachelor of science in Biology he remained at Georgetown University to attend its school of medicine. He completed an internship and General Surgery residency at Northwestern University in Evanston, Illinois, spending two years of his time there working in a basic science laboratory studying the development of pancreatic cancer. He also attended Northwestern’s Kellogg School of Management, earning a Masters in Business Administration with a focus on Healthcare Management and Strategy.[1]
Following his time at Northwestern, Dr. Kennedy completed a two-year surgical oncology fellowship at Memorial Sloan Kettering Cancer Center with a focus on gastric, pancreatic, and hepatobiliary malignancies. He pursued and completed a second fellowship there in advanced minimally invasive surgery, developing skills in advanced laparoscopic, endoscopic, and robotic techniques.
After completing his education, Dr. Kennedy spent six years as Assistant Professor of Surgery at Montefiore Medical Center/Albert Einstein College of Medicine in its section of upper gastrointestinal and pancreas surgery. Today he is an Assistant Professor of Surgery in the Gastrointestinal Oncology Program at Rutgers Cancer Institute.
Research
Dr. Kennedy has been actively involved in clinical trials throughout his career, including serving as principal investigator on a Phase II clinical trial utilizing CRS and HIPEC for patients with peritoneal surface malignancy from peritoneal mesothelioma, pseudomyxoma peritonei, appendiceal cancer, colon cancer, and gastric cancer.
His recent publications include the following articles on peritoneal mesothelioma:
Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study
Gazivoda, V. P., Kangas-Dick, A. W., Greenbaum, A. A., Roshal, J., Chen, C., Moore, D. F., Langan, R. C., Kennedy, T. J., Minerowicz, C. & Alexander, H. R., Sep 2022, In Journal of Surgical Research. 277, p. 131-137 7 p.
Treatment of Patients with Malignant Peritoneal Mesothelioma
Li, C. Y., Kennedy, T. & Alexander, H. R., Apr 1, 2022, In Journal of Clinical Medicine. 11, 7, 1891.
The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma.
Chicago Consensus Working Group, Jun 1, 2020, In: Cancer. 126, 11, p. 2547-2552 6 p.
